Component
WOMAC stiffness score in adults with XLH
WOMAC stiffness score in adults with XLH. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The WOMAC stiffness endpoint significantly improved versus placebo in the week-24 analysis.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"}
- experimental_model
- Randomized double-blind placebo-controlled phase 3 trial
- exposure
- Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis
- limitations
- FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.
- nutrient_topic
- Phosphorus research collection; topical membership is not evidence of a direct dietary effect. · Phosphorus
- organism
- Human
- plain_language
- Stiffness improved in the treated XLH group.
- primary_references
- [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
- tissue_or_cell_type
- 134 symptomatic adults with X-linked hypophosphatemia
Phosphorus: metabolism, signaling and nutrient connections (2026-09-17) · lines 1219–1230
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled phase 3 trial · source_derived_draft · unverified_draft
### phosphorus-burosumab-stiffness The WOMAC stiffness endpoint significantly improved versus placebo in the week-24 analysis. Condition category: normal nutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect. plain_language: Stiffness improved in the treated XLH group. organism: Human tissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia experimental_model: Randomized double-blind placebo-controlled phase 3 trial limitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation. exposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis evidence_span: {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"} [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.